Triple
T11074261
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | HER2 receptor |
E261824
|
entity |
| Predicate | targetOfDrug |
P37016
|
FINISHED |
| Object |
neratinib
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
|
E902878
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69d6aa9983c08190b0ef61603b69feac |
elicitation | completed |
| NER | batch_69d7994e32fc8190a6591d9e82b68f75 |
ner | completed |
| NED1 | batch_69e3c8cc77988190aad54f56dbd0f8cf |
ned_source_triple | completed |
| NED2 | batch_69e3d014a644819092c76aa02b573ca9 |
ned_description | completed |
| NEDg | batch_69e3cefc00148190a1850dc6e31523c3 |
nedg | completed |
Created at: April 8, 2026, 9:26 p.m.